Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.0
Journals
JCM
Special Issues
Novel Therapeutic Targets with Inflammatory Bowel Diseases
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Novel Therapeutic Targets with Inflammatory Bowel Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 440

Special Issue Editors

Dr. Konstantinos H. Katsanos

E-Mail Website
Guest Editor
Department of Gastroenterology, University Hospital of Ioannina, 455 00 Ioannina, Greece
Interests: inflammatory bowel disease; ulcerative colitis; gastroenterology; endoscopy; colorectal cancer; gastrointestinal diseases; hepatology
Special Issues, Collections and Topics in MDPI journals
Dr. Fotios S. Fousekis

E-Mail Website
Co-Guest Editor
Department of Gastroenterology and Hepatology, University of Ioannina, Ioannina, Greece
Interests: inflammatory bowel disease; endoscopy; ulcerative colitis; Crohn’s disease; mucosal immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic conditions with a significant impact on patients' quality of life. Despite advances in understanding the pathophysiology of IBD, current treatments often lack long-term efficacy.

This Special Issue aims to identify and explore innovative therapeutic targets that can overcome these challenges, focusing on immune dysregulation, gut microbiome interactions, genetic predisposition and environmental triggers. It also focuses on prognostic models for evaluating current treatments, the role of molecular endoscopy in predicting IBD progression and tailoring therapy, novel anti-fibrotic agents, and studies promoting personalised treatment approaches for IBD patients.

In this Special Issue, we invite researchers and clinicians to submit original research articles, reviews and systematic reviews that address these areas and advance the development of novel therapeutic targets in IBD. Through this collaboration, we aim to promote novel treatment and therapeutic strategies that improve long-term outcomes and quality of life for patients.

We look forward to your contributions to this Special Issue.

Prof. Dr. Konstantinos H. Katsanos
Dr. Fotios S. Fousekis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • Crohn’s disease
  • ulcerative colitis
  • colorectal
  • intestinal bowel disease
  • mucosal im-munology
  • molecular endoscopy
  • fibrosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

20 pages, 535 KiB  
Review
Intestinal Fibrosis in Crohn’s Disease: Pathophysiology, Diagnosis, and New Therapeutic Targets
by Fotios S. Fousekis, Konstantinos Mpakogiannis, Ioanna Nefeli Mastorogianni, Georgios D. Lianos, Dimitrios K. Christodoulou and Konstantinos H. Katsanos
J. Clin. Med. 2025, 14(12), 4060; https://doi.org/10.3390/jcm14124060 (registering DOI) - 8 Jun 2025
Abstract
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that often leads to intestinal fibrosis, an irreversible complication associated with strictures and the need for surgical intervention. Fibrosis occurs due to prolonged inflammation and abnormal wound healing, involving complex interactions [...] Read more.
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that often leads to intestinal fibrosis, an irreversible complication associated with strictures and the need for surgical intervention. Fibrosis occurs due to prolonged inflammation and abnormal wound healing, involving complex interactions between immune cells, mesenchymal cells, cytokines, and the gut microbiota. Key fibrogenic mechanisms include the activation of fibroblasts and myofibroblasts, cytokine signaling, and disrupted turnover of the extracellular matrix. Advancements in imaging techniques, such as MRI and CT enterography, have improved the detection and monitoring of fibrosis. Additionally, molecular techniques targeting fibroblast activation proteins show promise as a new imaging method. However, there are currently no approved anti-fibrotic therapies for CD. Emerging strategies focus on key pathways and novel therapeutic targets, including growth factor modulators, intracellular enzyme and kinases modulators, and interventions targeting the modulation of inflammation and extracellular matrix, which are being evaluated in preclinical and clinical settings. This review discusses the pathophysiology, diagnostic advancements, and therapeutic perspectives related to intestinal fibrosis in CD, emphasizing the urgent need for targeted anti-fibrotic therapies to prevent long-term complications and improve the life quality of patients. Full article
(This article belongs to the Special Issue Novel Therapeutic Targets with Inflammatory Bowel Diseases)
12 pages, 826 KiB  
Review
Diagnosing Ulcerative Colitis: Should We Go Beyond the Surface?
by Vincenzo Villanacci, Giovanni Maconi, Lucrezia Laschi and Gabrio Bassotti
J. Clin. Med. 2025, 14(11), 3690; https://doi.org/10.3390/jcm14113690 - 24 May 2025
Viewed by 220
Abstract
Ulcerative colitis is a chronic inflammatory bowel disease characterized by continuous mucosal inflammation of the large bowel. However, by conducting a literature search, it emerges that, although being considered a primary mucosal disorder in a subset of patients, the inflammatory process may extend [...] Read more.
Ulcerative colitis is a chronic inflammatory bowel disease characterized by continuous mucosal inflammation of the large bowel. However, by conducting a literature search, it emerges that, although being considered a primary mucosal disorder in a subset of patients, the inflammatory process may extend beyond the mucosal surface. For this reason, we reviewed the pertinent literature to evaluate the evidence related to the aforementioned topic. The literature analysis confirmed that, although ulcerative colitis has to be defined as a primary mucosal disease due to its consistent mucosal onset, it can involve deeper layers of the colonic wall. The inefficacy of anti-inflammatory therapies in a considerable proportion of patients, along with the lack of histologic healing and the persistence of inflammatory status and colonic wall thickening at imaging despite mucosal healing, has led to consider an extension of the disease process beyond the mucosal layer. The recent application of more accurate diagnostic tools, both histological and radiological (i.e., intestinal ultrasound and magnetic resonance), has the potential to underline the early signs of disease extension and progression in order to improve ulcerative colitis clinical management. Full article
(This article belongs to the Special Issue Novel Therapeutic Targets with Inflammatory Bowel Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop